Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OYSTER PT PHARM (OYST : NSDQ)

• Company Description    Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company's lead product candidate, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Oyster Point Pharma Inc. is based in Princeton, New Jersey. Number of Employees: 303

• Price / Volume Information    Yesterday's Closing Price: $3.99 Daily Weekly Monthly 20 Day Moving Average: 121,670 shares Shares Outstanding: 26.67 (millions) Market Capitalization: $106.41 (millions) Beta: 0.99 52 Week High: $21.01 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -42.92% -37.50% 12 Week -63.56% -59.05% Year To Date -78.15% -73.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 202 CARNEGIE CENTER SUITE 109 - PRINCETON,NJ 08540 USA ph: 609-382-9032 fax: - investors@oysterpointrx.com http://www.oysterpointrx.com

• General Corporate Information    Officers Jeffrey Nau - Chief Executive Officer; President and Director Donald Santel - Chair of the Board Daniel Lochner - Chief Financial Officer George Eliades - Director Michael Atieh - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 69242L106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 26.67 Most Recent Split Date: (:1) Beta: 0.99 Market Capitalization: $106.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -146.58% vs. Previous Quarter: -11.80% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -59.01% ROE 03/31/22 - -116.58 12/31/21 - -71.97 09/30/21 - -50.00 ROA 03/31/22 - -68.61 12/31/21 - -52.71 09/30/21 - -43.74 Current Ratio 03/31/22 - 7.27 12/31/21 - 7.47 09/30/21 - 12.51 Quick Ratio 03/31/22 - 7.09 12/31/21 - 7.26 09/30/21 - 12.51 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -475.87 12/31/21 - -410.20 09/30/21 - -450.46 Book Value 03/31/22 - 2.10 12/31/21 - 3.80 09/30/21 - 5.26 Inventory Turnover 03/31/22 - 0.73 12/31/21 - 1.00 09/30/21 - - Debt-to-Equity 03/31/22 - 1.62 12/31/21 - 0.90 09/30/21 - 0.30 Debt-to-Capital 03/31/22 - 61.81 12/31/21 - 47.43 09/30/21 - 23.36

Powered by Zacks Investment Research ©